Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small...
This could be a game changer. Marketcap of Lexicon Pharm that produces Inpefa is only $538M with plenty of cash on hand. Competitor drugs Jardiance from NYSE:LLY and Farxiga from NASDAQ:AZN did over $6B and $4B revenue respectively in 2022 and expected to grow quite a bit over the next few years. Inpefa received FDA approval and was rolling out...
NASDAQ:LXRX
Technical Analysis for LXRX:
If LXRX breaks above the bullish line of $4.00, it may indicate a bullish signal and suggest potential upward price movement. In this scenario, the target prices (TP) could be set at $4.50 and $6.00 as bullish targets.
Conversely, if LXRX breaks below the bearish line of $2.87, it may suggest a bearish signal and imply...
LXRX. Approved Drug. More drugs coming to market. Selling new drug starts in June.
High institutional value. High Insider Value. etc etc
Rocket is fueling.
The first step towards profitability for biotech companies is FDA approval since it allows these companies to start realizing revenues from their treatments. One of the biotech stocks that is set to earn revenues for the first time is Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) whose heart failure treatment was approved by the FDA last Friday. Although LXRX stock...
Premarket this morning I shorted into the previous high of 3.79 and the $4.00. My targets were 3.55 and 3.80. which were the 3.50 support level and the previous high of 3.79. The targets were quickly hit. I want some insight on how to determine that this stock was going as far as it did, all the way down to 2.67.
Short term and long term Force Index turned positive and the most recent candles tested the 200MA with a hammer doji followed by a green candle that took out the .61 fib level.
OBV is above the 20EMA and angled up as is the D+ and ADX with a 34 value suggesting a strong trend.
target: $3.48, $3.87
NASDAQ:LXRX
LXRX has gained over 100% in the past month
However it appears to be forming a double top
in a potential short trade setup on the two hour chart.
The K/D crossover on the hot RSI oscillator provides
confirmation.
Short Sale Volume is rising in the past two days.
Findamentals - LXRX has a new medication for heart failure
a common medical problem...
Just like TXMD, I like Lexicon too. BB is an indicator that even though I don't rely on, but together with RSI -and some other factors and market conditions- it's not a bad idea to consider looking at it. The vertical lines represent the buy and sell moments on this chart, please note where the price was at those points on the Bollinger Band and what value we saw...
NASDAQ:LXRX
Possible Scenario: LONG
Evidence: Price Action, Momentum
TP1: 4.40$
TP2: 4.80$
TP3: 5.80
Call options, Strike 5$, 01/21/2022
Call options, Strike 4$, 09/17/2021
*This is my idea and could be wrong 100%.
Possibility to gain again?
It looks like it want to crawl up on a support line (green).
I've packed bags here a little.
Indicators are almost reversed to bullish.
But it still can go lower if it breaks the support line.
Remember to have a stop loss below the support line.
There is a big gap below 5.60.
There also could happen a bear trap, quick fall and then...
I can see a wave count
Wave has clean wave 3 up
Followed by a rather not flat but a retrace zig-zag type wave 4 down
If the price goes above the box, I will buy it at the marked location
Possible Buy Setup on #LXRX
I can see a Wave 3 and 4
This could lead to a new wave 5
Entry: $7.70
First Target: $8.80
If achieved close half
and move SL to Breakeven
Daily Chart Analysis:
This stock is coming off a lengthy distribution phase between 5.99 – 20.00 which lasted around 3580 days. The price then made it downwards move and found a support @ around 1.18. Over the past 530 days, the price was in an accumulation phase between 1.18 – 4.15 and after the occurrence of a Golden Cross, a sharp breakout move upwards of 121%...
I'm all in on this one, seems like an amazing risk to reward ratio, the stocks is hugely undervalued. The stock shows huge institutional interest, with it being hugely oversold, leads me to believe it's an amazing investment.
